Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 + Reirradiation in Recurrent Glioblastoma
NCT01666600Phase 2Terminated
- Sponsor
- Prof. Dr. Wolfgang Wick
- Start
- Aug 2012
- Primary completion
- Mar 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nintedanib in glioblastoma (GBM) (2 arms), sponsored by Prof. Dr. Wolfgang Wick. Primary endpoint: Maximal Tolerated Dose at day 17. Started Aug 2012; status: terminated.
02
Drugs
nintedanib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01666600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666600.